GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (NYSE:FMS) » Definitions » Valuation Rank

Fresenius Medical Care AG (Fresenius Medical Care AG) Valuation Rank


View and export this data going back to 1996. Start your Free Trial

What is Fresenius Medical Care AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Fresenius Medical Care AG Valuation Rank Related Terms

Thank you for viewing the detailed overview of Fresenius Medical Care AG's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresenius Medical Care AG (Fresenius Medical Care AG) Business Description

Address
Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.
Executives
Helen Pring Giza Board of Directors